Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3764-3773

  Vogelbacher, Regina ^a   Meister, Silke ^a   Gückel, Eva ^a   Starke, Charlotte ^a   Wittmann, Sandra ^a   Stief, Andrea ^a   Voll, Reinhard ^a   Daniel, Christoph ^a   Hugo, Christian ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Bortezomib; Humoral response; Renal transplantation model; Sirolimus

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN G; PLACEBO; RAPAMYCIN; ALLOANTIBODY; BORONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BONE MARROW; CHRONIC ACTIVE ANTIBODY MEDIATED REJECTION; CHRONIC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; GLOMERULAR STRUCTURE; HELPER CELL; HISTOPATHOLOGY; HUMORAL IMMUNITY; INFLAMMATORY INFILTRATE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MACROPHAGE; MALE; MONOTHERAPY; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; RAT; SPLEEN; ALLOTRANSPLANTATION; ANIMAL; CHRONIC DISEASE; DRUG EFFECT; FISCHER 344 RAT; GRAFT REJECTION; IMMUNOLOGY; LEWIS RAT; LYMPHOCYTE DEPLETION; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; BORONIC ACIDS; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; PLASMA CELLS; PYRAZINES; RATS; RATS, INBRED F344; RATS, INBRED LEW; SIROLIMUS; SPLEEN; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 79952198748     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq230     Document Type: Article

References (29)

1. Feucht HE. Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646-652 (Pubitemid 36745236)
2. Chang AT, Platt JL. The role of antibodies in transplantation. Transplant Rev (Orlando) 2009
3. Terasaki P, Mizutani K. Antibody mediated rejection: Update 2006. Clin J Am Soc Nephrol 2006; 1: 400-403
4. Heidt S, Roelen DL, Eijsink C et al. Effects of immunosuppressive drugs on purified human B cells: Evidence supporting the use of MMF and rapamycin. Transplantation 2008; 86: 1292-1300
5. Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280 (Pubitemid 46743692)
6. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: Treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23: 34-46
7. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755 (Pubitemid 351951516)
8. Joosten SA, van Dixhoorn MG, Borrias MC et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002; 160: 1301-1310 (Pubitemid 34411634)
9. Koch M, Broecker V, Heratizadeh A et al. Induction of chronic renal allograft injury by injection of a monoclonal antibody against a donor MHC Ib molecule in a nude rat model. Transpl Immunol 2008; 19: 187-191
10. Joosten SA, van Ham V, Borrias MC et al. Antibodies against mesangial cells in a rat model of chronic renal allograft rejection. Nephrol Dial Transplant 2005; 20: 692-698 (Pubitemid 40520644)
11. Johnson RJ, Garcia RL, Pritzl P et al. Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. Am J Pathol 1990; 136: 369-374 (Pubitemid 20074611)
12. Johnson RJ, Iida H, Alpers CE et al. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991; 87: 847-858
13. Wittmann S, Daniel C, Braun A et al. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 2008; 108: E45-e56 (Pubitemid 351346991)
14. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723 (Pubitemid 29082898)
15. Iruela-Arispe L, Gordon K, Hugo C et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995; 147: 1715-1727
16. Nangaku M, Alpers CE, Pippin J et al. A new model of renal microvascular endothelial injury. Kidney Int 1997; 52: 182-194 (Pubitemid 27321829)
17. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209
18. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760 (Pubitemid 351347767)
19. Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C et al. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 2007; 16: 775-781 (Pubitemid 350069789)
20. Alperovich G, Rama I, Lloberas N et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 2007; 16: 18-24 (Pubitemid 46178084)
21. Pescovitz MD, Book BK, Henson S et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 2003; 3: 497-500 (Pubitemid 36560104)
22. Koch M, Mengel M, Poehnert D et al. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 2007; 83: 498-505 (Pubitemid 46667854)
23. Battaglia M, Stabilini A, Migliavacca B et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-8347 (Pubitemid 44893795)
24. Meister S, Schubert U, Neubert K et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792 (Pubitemid 46383406)
25. Maseda D, Meister S, Neubert K et al. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 2008; 15: 600-612 (Pubitemid 351267310)
26. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- And cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761
27. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561
28. Arpinati M, Chirumbolo G, Nicolini B et al. Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade). Bone Marrow Transplant 2009; 43: 253-259
29. Blanco B, Perez-Simon JA, Sanchez-Abarca LI et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575-3583